Journal of Clinical Oncology, Vol 23, No 3 (January 20), 2005: pp. 576-584
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.01.180
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
A. Le Cesne,
J.Y. Blay,
I. Judson,
A. Van Oosterom,
J. Verweij,
J. Radford,
P. Lorigan,
S. Rodenhuis,
I. Ray-Coquard,
S. Bonvalot,
F. Collin,
J. Jimeno,
E. Di Paola,
M. Van Glabbeke,
O.S. Nielsen
From the Institut Gustave Roussy, Villejuif; Centre Leon Bérard, Lyon; Centre Leclerc, Dijon, France; Royal Marsden Hospital, London; Christie Hospital, Manchester; Weston Park Hospital, Sheffield, UK; U.Z. Gasthuisberg, Leuven; EORTC Data Center, Brussels, Belgium; Rotterdam Cancer Institute, Rotterdam; Antoni van Leuuwenhoekhuis, Amsterdam, the Netherlands; Pharma-Mar, Tres Cantos, Spain; Aarhus University Hospital, Aarhus, Denmark
Address reprint requests to Axel Le Cesne, MD, Department of Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France; e-mail: lecesne{at}igr.fr
PURPOSE: This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m2 as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced soft tissue sarcoma.
PATIENTS AND METHODS: Patients with documented progressive advanced soft tissue sarcoma received ET-743 as second- or third-line chemotherapy. Antitumor activity was evaluated every 6 weeks until progression, excessive toxicity, or patient refusal.
RESULTS: One hundred four patients from eight European institutions were included in the study (March 1999 to November 2000). A total of 410 cycles were administered in 99 assessable patients. Toxicity mainly involved reversible grade 3 to 4 asymptomatic elevation of transaminases in 40% of patients, and grade 3 to 4 neutropenia was observed in 52% of patients. There were eight partial responses (PR; objective regression rate, 8%), 45 no change (NC; > 6 months in 26% of patients), and 39 progressive disease. A progression arrest rate (PR + NC) of 56% was observed in leiomyosarcoma and 61% in synovialosarcoma. The median duration of the time to progression was 105 days, and the 6-month progression-free survival was 29%. The median duration of survival was 9.2 months.
CONCLUSION: ET-743 seems to be a promising active agent in advanced soft tissue sarcoma, with no cumulative toxicities. The 6-months progression-free survival observed in advanced soft tissue sarcoma compares favorably with those obtained with other active drugs tested in second-line chemotherapy in previous European Organisation for the Research and Treatment of Cancer trials. The median overall survival was unusually long in these heavily pretreated patients mainly due to the high number of patients who benefit from the drug in terms of tumor control.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J.-Y. Blay and A. Le Cesne
Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven
Oncologist,
October 1, 2009;
14(10):
1013 - 1020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. D. Demetri, S. P. Chawla, M. von Mehren, P. Ritch, L. H. Baker, J. Y. Blay, K. R. Hande, M. L. Keohan, B. L. Samuels, S. Schuetze, et al.
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
J. Clin. Oncol.,
September 1, 2009;
27(25):
4188 - 4196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Le Cesne, M. Van Glabbeke, J. Verweij, P. G. Casali, M. Findlay, P. Reichardt, R. Issels, I. Judson, P. Schoffski, S. Leyvraz, et al.
Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
J. Clin. Oncol.,
August 20, 2009;
27(24):
3969 - 3974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Grosso, R. Sanfilippo, E. Virdis, C. Piovesan, P. Collini, P. Dileo, C. Morosi, J. C. Tercero, J. Jimeno, M. D'Incalci, et al.
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
Ann. Onc.,
August 1, 2009;
20(8):
1439 - 1444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Chuk, F. M. Balis, and E. Fox
Trabectedin
Oncologist,
August 1, 2009;
14(8):
794 - 799.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Forouzesh, M. Hidalgo, Q. Chu, A. Mita, M. Mita, G. Schwartz, J. Jimeno, J. Gomez, V. Alfaro, C. Lebedinsky, et al.
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Clin. Cancer Res.,
May 15, 2009;
15(10):
3591 - 3599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Ocio, P. Maiso, X. Chen, M. Garayoa, S. Alvarez-Fernandez, L. San-Segundo, D. Vilanova, L. Lopez-Corral, J. C. Montero, T. Hernandez-Iglesias, et al.
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
Blood,
April 16, 2009;
113(16):
3781 - 3791.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Thomas, A. Gronchi, and B. O'Sullivan
A Multidisciplinary Approach to Retroperitoneal Sarcomas: Current State-of-the-Art
ASCO Educational Book,
January 1, 2009;
2009(1):
701 - 708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. Blay, M. von Mehren, B. L. Samuels, M. P. Fanucchi, I. Ray-Coquard, B. Buckley, L. Gilles, C. Lebedinsky, Y. A. Elsayed, and A. Le Cesne
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Clin. Cancer Res.,
October 15, 2008;
14(20):
6656 - 6662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. von Mehren, R. J. Schilder, J. D. Cheng, E. Temmer, T. M. Cardoso, F. G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R. B. Cohen
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
Ann. Onc.,
October 1, 2008;
19(10):
1802 - 1809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Ray-Coquard, A. Le Cesne, J. S. Whelan, P. Schoffski, B. N. Bui, J. Verweij, S. Marreaud, M. van Glabbeke, P. Hogendoorn, and J.-Y. Blay
A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens
Oncologist,
April 1, 2008;
13(4):
467 - 473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Verweij
Other Endpoints in Screening Studies for Soft Tissue Sarcomas
Oncologist,
April 1, 2008;
13(suppl_2):
27 - 31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Casali
Clinical Decision-making in Rare Tumors: What Is Needed from Clinical Trials
ASCO Educational Book,
January 1, 2008;
2008(1):
530 - 533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tascilar, W. J. Loos, C. Seynaeve, J. Verweij, and S. Sleijfer
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
Oncologist,
November 1, 2007;
12(11):
1351 - 1360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Soares, A. E. Escargueil, V. Poindessous, A. Sarasin, A. de Gramont, D. Bonatto, J. A. P. Henriques, and A. K. Larsen
From the Cover: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
PNAS,
August 7, 2007;
104(32):
13062 - 13067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. G. Maki
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
Oncologist,
August 1, 2007;
12(8):
999 - 1006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Herrero, C. Martin-Castellanos, E. Marco, F. Gago, and S. Moreno
Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin
Cancer Res.,
August 15, 2006;
66(16):
8155 - 8162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay
ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas
Oncologist,
November 1, 2005;
10(10):
827 - 832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sleijfer, C. Seynaeve, and J. Verweij
Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care
Oncologist,
November 1, 2005;
10(10):
833 - 841.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Verweij
Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas?
J. Clin. Oncol.,
August 20, 2005;
23(24):
5420 - 5423.
[Full Text]
[PDF]
|
 |
|
|